Approved indications
Rystiggo is FDA-approved for the treatment of generalized myasthenia gravis in adults who test positive for anti-acetylcholine receptor (AChR) or anti–muscle-specific tyrosine kinase (MuSK) antibodies.

Off-label uses
As a relatively new FcRn inhibitor, there are no well-established, routine off-label uses in clinical practice yet; use outside its approved indication is generally limited to research settings or highly specialized care and should be considered experimental.

Efficacy expectations
In clinical trials, many patients began to notice improvement in myasthenia gravis symptoms within the first few weeks of the 6-week treatment cycle, with reductions in symptom scores (such as MG-ADL) and improved muscle strength compared with placebo. Benefits are time-limited and may wane after the treatment cycle, so repeated treatment cycles may be needed based on symptoms. Compared with other therapies for generalized myasthenia gravis, such as efgartigimod (another FcRn blocker), IVIg, or plasma exchange, Rystiggo provides a targeted, non-steroidal option given subcutaneously that can reduce IgG autoantibodies without broadly suppressing all immune function like chronic steroids or some immunosuppressants.

Typical dosing
Rystiggo is given as a once-weekly subcutaneous infusion for six weeks, with a weight-based dose of 7 mg/kg for patients weighing 40 to less than 100 kg and 10 mg/kg for patients weighing 100 kg or more. It is prepared and administered by a healthcare professional using subcutaneous infusion, typically over a set period, and does not need to be taken with food because it is not an oral medication.

Special dosing instructions
Before each treatment cycle, the prescriber evaluates symptoms and timing of previous cycles to decide when to repeat therapy; treatment intervals may vary based on clinical response. Patients should inform their healthcare provider about infections, recent vaccines, or upcoming surgeries, as the dosing schedule may need adjustment. Vaccinations should ideally be updated before starting therapy, and live or live-attenuated vaccines should generally be avoided during and soon after treatment.

Missed dose guidance
If a dose is missed, patients should contact their healthcare provider promptly for instructions; the dose is typically rescheduled rather than doubled or taken closer together without medical advice.

Overdose
In case of suspected overdose or administration of more than the prescribed amount, patients should seek immediate medical attention or contact a poison control center; monitoring for side effects, especially infection or infusion reactions, will guide further management.

Common side effects
Common side effects include headache, infections of the upper respiratory tract or common cold–like symptoms, diarrhea, fever, and reactions at the injection or infusion site (such as redness, pain, or swelling). These effects often start during or within a few days after treatment doses and are usually mild to moderate in intensity.

Serious or rare adverse effects
Because Rystiggo lowers IgG levels, it can increase the risk of infections; serious infections, including those requiring hospitalization, can occur and require immediate medical attention if symptoms such as high fever, chills, shortness of breath, or severe fatigue develop. Hypersensitivity or allergic reactions, including rash, itching, swelling, dizziness, or trouble breathing, can also occur and may require urgent care.

Warnings and precautions
Patients should be evaluated for active infections before starting therapy and monitored for signs of infection during and after treatment; treatment may need to be delayed or interrupted if a serious infection occurs. Use in pregnancy has limited human data; because the drug affects IgG, potential effects on the fetus and newborn immunity should be carefully weighed, and decisions about use during pregnancy or breastfeeding should be individualized with the prescriber. Dose adjustments are not routinely defined for kidney or liver disease, but caution and closer monitoring may be appropriate in significant organ impairment. Live or live-attenuated vaccines should generally be avoided during treatment and for a period afterward, and vaccination status should be reviewed before starting therapy.

Comparative safety
Compared with many traditional immunosuppressants or chronic high-dose steroids, Rystiggo offers a more targeted mechanism, but infection risk, headache, and infusion/injection reactions remain important concerns; long-term safety data are more limited than for older agents.

Reporting and safety updates
Side effects can be reported to the FDA MedWatch program or to the manufacturer as directed in the prescribing information, and patients and clinicians can check FDA and manufacturer communications for updated safety information and new warnings over time.

Drug and vaccine interactions
Because Rystiggo lowers IgG levels, it may reduce the effectiveness of vaccines, particularly live or live-attenuated vaccines, which are generally not recommended during treatment and for a period afterward. Interactions with many standard oral medications are not expected via common liver enzyme pathways, but changes in IgG may affect other IgG-based therapies such as monoclonal antibodies or immunoglobulin products; clinicians may need to adjust timing when combining these. Patients should tell their healthcare provider about all prescription and over-the-counter medicines, vitamins, and herbal supplements they use.

Food, alcohol, and procedures
No specific food or alcohol interactions are known, but moderation in alcohol use is generally advised in people with chronic neuromuscular or autoimmune disease. For planned surgeries or major procedures, timing of Rystiggo infusions and infection risk should be reviewed with the surgical and neurology teams.

Precautions and conditions making use less safe
Use requires caution in patients with current or recurrent serious infections, significantly weakened immune systems, or those receiving other strong immunosuppressive drugs, because of added infection risk. Patients with a history of recurrent respiratory or sinus infections, chronic lung disease, or poorly controlled diabetes may need closer monitoring. Vaccination history should be reviewed, and non-live vaccines should ideally be administered before starting treatment when feasible.

Monitoring needs
Clinicians typically monitor for clinical response in myasthenia gravis symptoms, signs of infection, and any hypersensitivity reactions during and after each infusion. Laboratory monitoring may include periodic blood counts or other tests based on overall health status and concomitant medications, though routine intensive lab monitoring is generally less than with many traditional immunosuppressants.

Q: How quickly does Rystiggo start working for generalized myasthenia gravis?
A: Many patients in studies noticed some improvement in symptoms within the first few weeks of the 6-week treatment cycle, though the exact timing and degree of benefit differ from person to person.

Q: How is Rystiggo given and how long does treatment last?
A: Rystiggo is given by a healthcare professional as a subcutaneous infusion once a week for six weeks, and additional treatment cycles may be repeated later based on how long symptom relief lasts.

Q: Will I need to stop my other myasthenia gravis medicines when I start Rystiggo?
A: Many people continue baseline therapies such as pyridostigmine, steroids, or other immunosuppressants, and any changes to existing medications should be made only in consultation with the prescribing neurologist.

Q: What are the most important side effects to watch for with Rystiggo?
A: The key concerns are infections (such as fevers, chills, or new cough), headaches, and infusion or injection-site reactions, and any signs of serious infection or allergic reaction should prompt immediate medical attention.

Q: Can I receive vaccines while being treated with Rystiggo?
A: Live or live-attenuated vaccines are generally avoided during and shortly after treatment, and other vaccines may be less effective, so vaccination plans should be discussed with your healthcare provider before and during therapy.

Storage
Rystiggo is typically stored in a refrigerator at 2°C to 8°C (36°F to 46°F), protected from light, and should not be frozen or shaken; it should be kept in the original carton until use and allowed to reach room temperature before administration as directed by the healthcare team.

Disposal
Any unused solution, used syringes, needles, or infusion sets should be discarded in a sharps container or according to local regulations and instructions from a healthcare provider or pharmacist; Rystiggo should not be thrown into household trash or poured down sinks or toilets.